Randomized Phase II Trial of S-1 Versus S-1 plus Oxaliplatin (Sox) in Patients with Gemcitabine Refractory Pancreatic Cancer

Trial Profile

Randomized Phase II Trial of S-1 Versus S-1 plus Oxaliplatin (Sox) in Patients with Gemcitabine Refractory Pancreatic Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Oxaliplatin (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Yakult Honsha
  • Most Recent Events

    • 06 Jun 2017 Results of pooled analysis of three studies including this study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2013 According to a Yakult Honsha media release, the company has submitted supplemental new drug applications relating to an additional indication for pancreatic cancer, with respect to its products, Campto (40mg and 100mg), Elplat (50mg, 100mg and 200mg), and Levofolinate [Yakult] (25mg and 100mg), to the Japanese Ministry of Health, Labor and Welfare (MHLW).
    • 30 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top